Company intelligence / Profile preview

WallabyPhenox

Laguna Hills, California, United States

Ownership: Private
Employees: ~700
Development stage: Other

Overview

WallabyPhenox conducts rigorous clinical trials for stroke and neurovascular device products. Its pRESET thrombectomy device demonstrated non-inferiority to Solitaire in the PROST trial for stroke thrombectomy. The company launched the antithrombogenic Pegasus HPC Stent System in 2022, offering evidence-based effectiveness. New studies on implant coating technologies could reduce the need for antiplatelet therapy in flow-diverter treatments[7][12].

Therapeutic areas: CardiovascularNeurology
Modalities: Device
Industry: Surgical Medical Devices

Partnerships

Japan Lifeline (JLL)

Beyond the preview

Go deeper on WallabyPhenox.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WallabyPhenox.

Explore the full profile